Intelligent Bio Solutions Inc.
INBS Healthcare Medical Devices
Intelligent Bio Solutions Inc.’s revenue for fiscal 2026 (year ended June 2026) was $4.2 million, up 38.1% from fiscal 2025. In the quarter to June 2026, revenue grew 51.1%, EPS grew 78.1% and free cash flow fell 31.6%, each against the same quarter a year earlier.
Follow INBS
Intelligent Bio Solutions Inc. (INBS) EV/Sales
As of 16 October 2026, Intelligent Bio Solutions Inc. (INBS) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −2.0× (December 2022) to 153× (January 2021); the current reading is higher than 14% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 0.4× | (87.40%) |
| FY2025 | 3.4× | — |
| FY2024 | −0.2× | — |
| FY2023 | 1.7× | (9.99%) |
| FY2022 | 1.9× | (87.34%) |
| FY2021 | 15.2× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.4× | 83.50% |
| Mar 2026 | 0.2× | (92.28%) |
| Dec 2025 | 3.1× | 5.96% |
| Sep 2025 | 2.9× | (16.05%) |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVNO enVVeno Medical Corporation compare | −63.5× |
| CODX Co-Diagnostics, Inc. compare | −1.2× |
| AMIX Autonomix Medical, Inc. compare | n/m |
| WOK WORK Medical Technology Group LTD compare | n/m |
| TBIO Telesis Bio Inc. compare | 0.1× |
| INBS Intelligent Bio Solutions Inc. | 0.2× |
| VVOS Vivos Therapeutics, Inc. compare | 0.4× |
| TRIB Trinity Biotech PLC compare | 3.0× |
| VNRX VolitionRX Limited compare | 4.0× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)